First to File and Beyond: Paragraph IV Business Strategies
|
|
- Florence Tucker
- 8 years ago
- Views:
Transcription
1 First to File and Beyond: Paragraph IV Business Strategies THOMSON REUTERS INTELLECTUAL PROPERTY & SCIENCE GENERICS & API INTELLIGENCE Benjamin Burck Research Analyst and Project Manager Generics & API Intelligence
2 Generics & API Intelligence at Thomson Reuters 20 years of expertise in global generics Unique research that tracks global generic API development and manufacturing activities Intelligence appears in Newport Premium database for: Strategy, Planning and Product Targeting Business Development & Licensing Competitive & Business Intelligence API Sourcing Patents & Intellectual Property Supports Life Sciences consulting projects Serves 300 customers operating in 43 countries Team based in Portland, Maine 2
3 Agenda Hatch-Waxman Basics Paragraph IV Strategies Market Realities Anticipating Competitors Examples 3
4 Orange Book Patent Listing 21 USC 355(b)(1) The applicant shall file with the application (NDA) the patent number and the expiration date of any patent which claims the drug for which the applicant submitted the application or which claims a method of using such drug and with respect to which a claim of patent infringement could reasonably be asserted if a person not licensed by the owner engaged in the manufacture, use, or sale of the drug. 4
5 Orange Book Patent Listing Patents that must be listed Active ingredient (drug substance) Formulation or composition (drug product) Method of approved use Patents that may not be listed Processes Packaging Intermediates 5
6 ANDA Patent Certification 21 USC 355(j)(2)(A)(vii) [An ANDA shall contain] a certification, in the opinion of the applicant and to the best of his knowledge, with respect to each patent which claims the listed drug or which claims a use for such listed drug for which the applicant is seeking approval (I) that such patent information has not been filed, (II) that such patent has expired, (III) of the date on which such patent will expire, or (IV) that such patent is invalid or will not be infringed by the manufacture, use, or sale of the new drug for which the application is submitted 6
7 Incentives and Protections 180-day market exclusivity First applicant to submit a substantially complete ANDA (first-to-file) May be shared by multiple applicants Subject to forfeiture 30-month stay of FDA approval If patent owner or NDA holder sues the ANDA applicant for patent infringement within 45 days of receiving notice of the Paragraph IV certification Runs from date of notification or expiration of NCE exclusivity May be lengthened or shortened by the court 7
8 ANDA Submission New Chemical Entity (NCE) Exclusivity Five year data exclusivity from the date of first NDA approval for products containing chemical entities never previously approved by FDA ANDAs with Paragraph IV certification may be submitted four years after regulatory approval (NCE -1), but may not receive approval until the expiration of the exclusivity period Other Exclusivities ANDAs may be submitted at any time, with or without Paragraph IV certification ANDAs may not receive approval until the expiration of the exclusivity period 8
9 Lawsuits such as these are an ordinary and expected part of the process of obtaining approval to commercialize a generic drug product in the United States. 9
10 First-Time Generic Approvals Source: Newport Premium 10
11 Possible Generic Paragraph IV Strategies Targets Everything Blockbusters Niche Products Formulation Therapeutic Class Limited API Limited Sales Market Position First filer Subsequent filer Limited competition Highly competitive market Line Extension 11
12 Generic Strategies We plan to continue to expand our Global Division through targeted ANDAs and a first-to-file and firstto-market strategy. Our products and product candidates are generally difficult to formulate and manufacture, providing certain barriers to entry for potential competitors. (Impax Laboratories, Form 10-K) The Niche Generics program is targeted on developing those generic drug products that are: Difficult to develop for technical reasons, especially injectable and ophthalmic dosage forms No or very limited API source (InnoPharma, Company Website) We believe that we can maximize the profitability of our generic product opportunities by continuing our proven track record of bringing to market high quality products that are difficult to formulate or manufacture, or for which the API is difficult to obtain. (Mylan, Form 10-K) The strategy in the Rx Pharmaceuticals segment is to be the first to market with those new products that are exposed to less competition because they have more difficult to develop formulations and cost much more to complete. (Perrigo, Form 10-K) We constantly seek to expand our range of generic products, with an emphasis on high-value products, including those with high barriers to entry. (Teva, Form 20-F) Our strategy in the U.S. is to develop generic pharmaceuticals that are difficult to formulate or manufacture or will complement or broaden our existing product lines. (Watson, Form 10-K) Differentiation is one of the rudiments that success thrives on and the company strategically selects difficult to develop, high technology products and niche markets to get ANDA approvals. (Wockhardt, Annual Report 2011) 12
13 Paragraph IV Reality Any product may be a generic target More companies are pursuing a Paragraph IV strategy Challenges to complex products are increasing Competition and specialization in the generic industry has led to products with $20 million or less in sales being considered opportunities Products may be targeted even before NDA approval 13
14 Gralise (gabapentin) First FDA Approval January 28, 2011 U.S. Product Launch October 10, 2011 First ANDA Submission October 31, 2011 NDA Holder Depomed US Sales (October December 2011) $ 0.5M Orange Book Patents Patent No Expiration Known ANDA Filers 6,340,475 September 19, ,488,962 June 20, ,635,280 September 19, ,723,340 October 25, ,731,989 October 25, ,438,927 February 26, 2024 Actavis, Incepta, Watson (Source: Depomed ) Source: Newport Premium 14
15 First Paragraph IV Patent Certifications Posted by FDA Source: Newport Premium 15
16 Corporate Groups Associated with Paragraph IV Patent Certifications Source: Newport Premium 16
17 Top Paragraph IV Filers by Group Source: Newport Premium 17
18 Market Reality Price erodes with each generic entrant Price erosion continues as the generic market matures Aggressive individual players can greatly affect the price for all First filer s market share advantage persists after additional generic entry Authorized generics are to be expected 18
19 Known ANDA Filers per Challenged Product Source: Newport Premium 19
20 First Filers Settlement leverage Limited competition at launch Higher initial price First Mover market share Marketing message 20
21 NCE-1 Opportunities Source: Newport Premium 21
22 2008 NCE -1 Products Trade Name Active Ingredient Dose Form # of Known P IV ANDAs Sensipar cinacalcet hydrochloride Tablet 1 Enablex darifenacin hydrobromide Extended-release tablet 3 Lovaza omega-3 acid ethyl esters Capsule 3 Cymbalta duloxetine hydrochloride Delayed-release capsule 9 Tarceva erlotinib hydrochloride Tablet 2 Lunesta eszopiclone Tablet 10 Fosrenol lanthanum carbonate hydrate Chewable tablet 4 Alimta pemetrexed disodium Injectable 4 Lyrica pregabalin Capsule 10 Source: Newport Premium 22
23 Subsequent Filers Travel a worn path Lower litigation costs Known legal arguments Settlement precedent More informed decisions Authorized generic deal? 23
24 Lunesta (eszopiclone) First FDA Approval December 15, 2004 NCE Exclusivity December 15, 2009 First ANDA Submission December 15, 2008 NDA Holder Sepracor (now Sunovion) US Sales (12 months ending September 30, 2011) $ 774.5M Orange Book Patents Patent No Expiration Known ANDA Filers 6,319,926 January 16, ,381,724 January 16, ,864,257 August 30, ,444,673 February 14, 2014 Generic Launch per Settlement November 30, 2013 (Source: IMS Health) Dr. Reddy's, Glenmark, Lupin, Mylan, Orchid, Roxane, Sun, Teva, Watson, Wockhardt Source: Newport Premium 24
25 Lunesta (eszopiclone): Mylan Paragraph IV Notification March 10, 2009 (Alphapharm) DMF Manufacturer Submission Date Matrix Laboratories March 25, 2008 Related Patents Primary Patent Patent Type Priority Date WO Process June 21, 2005 WO Formulation April 26, 2006 WO Process April 12, 2007 Newport First Associated Date June 21, 2005 Source: Newport Premium 25
26 Lunesta (eszopiclone): Teva Paragraph IV Notification February 9, 2009 DMF Manufacturer Submission Date TAPI Puerto Rico November 14, 2008 Related Patents Primary Patent Patent Type Priority Date WO Product (derivative) March 23, 2006 WO Process April 20, 2006 WO Process April 20, 2006 WO Process June 26, 2006 WO Formulation June 25, 2007 Newport First Associated Date March 23, 2006 Source: Newport Premium 26
27 Lunesta (eszopiclone): Some Others Involved Dr. Reddy s Laboratories Patent September 5, 2005 API Commercially Available in Newport March 9, 2007 DMF Submitted September 13, 2008 Farmak Patent (Czech Republic) August 11, 2000 API Commercially Available in Newport January 18, 2006 DMF Submitted March 7, 2008 Glenmark Patent January 17, 2006 Unconfirmed API Activity in Newport January 30, 2006 DMF Submitted August 4, 2008 Sun Pharmaceutical Industries API Commercially Available in Newport September 5, 2008 DMF Submitted November 29, 2008 Other Market Launches February 28, 2007 (India) Source: Newport Premium 27
28 Bystolic (nebivolol HCl) First FDA Approval December 17, 2007 NCE Exclusivity December 17, 2012 First ANDA Submission December 19, 2011 NDA Holder Forest Laboratories US Sales (12 months ending September 30, 2011) $ 341.1M Orange Book Patents Patent No Expiration Known ANDA Filers 5,759,580 June 2, ,545,040 December 17, 2021 (Source: IMS Health) Alkem, Amerigen, Glenmark, Hetero, Indchemie, Torrent, and Watson Source: Newport Premium 28
29 180-Day Exclusivity Forfeiture Generic exclusivity is forfeited for failure to market upon the later of: The earlier of: 75 days after approval of the first applicant s ANDA 30 months after the date of ANDA submission 75 days after any of the following with respect to any applicant with tentative approval: Court decision that the patent is invalid or not infringed (no further appeal) Settlement order or consent decree with judgment of invalidity or noninfringement Patent listing is withdrawn 29
30 Integrilin (eptifibatide) First FDA Approval December 15, 2004 First ANDA Submission September 30, 2008 NDA Holder ANDA Filer Schering (Merck) Teva Orange Book Patents Patent No Expiration 5,686,570 November 11, ,747,447 May 5, ,756,451 November 11, ,807,825 September 15, ,5968,902 June 2, 2015 Generic Launch per Settlement June 2, 2015 Source: Newport Premium 30
31 Kaletra (lopinavir/ritonavir) First FDA Approval October 28, 2005 First ANDA Submission December 23, 2008 NDA Holder ANDA Filer Abbott Mylan Orange Book Patents Patent No Expiration (including PED exclusivity) 5,541,206 Jan 30, ,648,497 Jan 15, ,886,036 May 19, ,914,332 Jun 13, ,037,157 Dec 26, ,284,767 Aug 15, ,703,403 Dec 26, ,148,359 Jan 19, ,364,752 May 10, ,025,899 Mar 26, 2028 Case status Stayed until July 1, 2014 Source: Newport Premium 31
32 Thank You! Benjamin Burck Research Analyst and Project Manager Thomson Reuters x35 thomsonreuters.com 32
NJIPLA s 25th Annual Pharmaceutical / Chemical Patent Practice Update First Applicant Generic Exclusivity and Forfeiture Thereof.
NJIPLA s 25th Annual Pharmaceutical / Chemical Patent Practice Update First Applicant Generic Exclusivity and Forfeiture Thereof December 7, 2011 Andrew S. Wasson Frommer Lawrence & HaugLLP Editor, FDALawyersBlog
More informationFDLI s IP Throughout the Drug Development Lifecycle
FDLI s IP Throughout the Drug Development Lifecycle Post-Marketing IP Protection & Enforcement: View From the Generic Side Janine A. Carlan Arent Fox LLP Topics To Be Discussed Hatch-Waxman Process Orange
More informationCredit Suisse Healthcare Conference
Credit Suisse Healthcare Conference November 14, 2013 Safe Harbor Statement 2 Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this
More informationOvercoming Restriction Requirements On Pharma Patents
Portfolio Media. Inc. 860 Broadway, 6th Floor New York, NY 10003 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com Overcoming Restriction Requirements On Pharma Patents
More informationGuidance for Industry 180-Day Exclusivity When Multiple ANDAs Are Submitted on the Same Day
Guidance for Industry 180-Day Exclusivity When Multiple ANDAs Are Submitted on the Same Day U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research
More informationPay-for-Delay: How Drug Company Pay-Offs Cost Consumers Billions. An FTC Staff Study January 2010. Federal Trade Commission ftc.
Pay-for-Delay: How Drug Company Pay-Offs Cost Consumers Billions An FTC Staff Study January 2010 Federal Trade Commission ftc.gov Summary Brand-name pharmaceutical companies can delay generic competition
More informationCase 8:09-cv-01193-MRP-MLG Document 8 Filed 10/27/2009 Page 1 of 14
Case :0-cv-0-MRP-MLG Document Filed //00 Page of California Street San Francisco, CA -0 0 Gail J. Standish (SBN: gstandish@winston.com Peter E. Perkowski (SBN: pperkowski@winston.com WINSTON & STRAWN LLP
More informationYou Know It Is Coming: Preparing for the Paragraph IV Letter
You Know It Is Coming: Preparing for the Paragraph IV Letter John Farrell, Fish & Richardson Matt Onaitis, Somaxon William Scarff, Allergan Jonathan Singer, Fish & Richardson Table of Contents Regulatory
More informationThe 505(b)(2) Drug Development Pathway:
The 505(b)(2) Drug Development Pathway: When and How to Take Advantage of a Unique American Regulatory Pathway By Mukesh Kumar, PhD, RAC and Hemant Jethwani, MS The 505(b)(2) regulation offers a less expensive
More informationCase 1:15-cv-01120-UNA Document 1 Filed 12/03/15 Page 1 of 49 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:15-cv-01120-UNA Document 1 Filed 12/03/15 Page 1 of 49 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE UNIMED PHARMACEUTICALS, LLC, BESINS HEALTHCARE INC., and BESINS
More informationUNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:99-mc-09999 Document 182 Filed 03/13/12 Page 1 of 39 PageID #: 10865 FOREST LABORATORIES, INC., FOREST LABORATORIES HOLDINGS, LTD., and JANSSEN PHARMACEUTICA N.V., v. Plaintiffs, UNITED STATES DISTRICT
More informationNew Chemical Entity Exclusivity Determinations for Certain Fixed- Combination Drug Products
New Chemical Entity Exclusivity Determinations for Certain Fixed- Combination Drug Products Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug
More informationPharmaceutical development is an expensive, time
Exclusivity Strategies in the United States and European Union by Carolyne Hathaway, John Manthei and Cassie Scherer Pharmaceutical development is an expensive, time consuming and uncertain process that
More informationReverse-payment patent settlements in the pharmaceutical industry: An analysis of US antitrust law and EU competition law
Reverse-payment patent settlements in the pharmaceutical industry: An analysis of US antitrust law and EU competition law By Michael Clancy,* Damien Geradin** and Andrew Lazerow*** In the pharmaceutical
More informationI N S I D E T H E M I N D S
I N S I D E T H E M I N D S Food and Drug Law Settlements and Negotiations Leading Lawyers on Complying with Federal Regulations, Negotiating Contracts with Manufacturers and Suppliers, and Defending Clients
More informationBrand Quality with Asian Advantages
Brand Quality with Asian Advantages ScinoPharm Taiwan, Ltd. No.1, Nan-Ke 8th Road, Tainan Science Park, Shan-Hua, Tainan, 74144, Taiwan TEL : 886-6-505-2888 FAX : 886-6-505-2898 Email Contact : mkt@scinopharm.com
More informationCase 2:12-cv-01941-GMN-GWF Document 1 Filed 11/09/12 Page 1 of 7
Case :-cv-0-gmn-gwf Document Filed /0/ Page of GORDON SILVER MOLLY M. REZAC, ESQ. Nevada Bar No. Email: mrezac@gordonsilver.com JUSTIN J. BUSTOS, ESQ. Nevada Bar No. 0 Email: jbustos@gordonsilver.com Suite
More informationThomas Hinchliffe, Pharm.D. CDR, U.S. Public Health Service Special Assistant to the Director Office of Generic Drugs Food and Drug Administration
Thomas Hinchliffe, Pharm.D. CDR, U.S. Public Health Service Special Assistant to the Director Office of Generic Drugs Food and Drug Administration Disclaimer & Disclosure Views presented are those of the
More informationWarren D.Woessner 612-373-6903 wwoessner@slwk.com. William F. Prout 612-373-6968 wprout@slwk.com
Warren D.Woessner 612-373-6903 wwoessner@slwk.com William F. Prout 612-373-6968 wprout@slwk.com Schwegman Lundberg Woessner & Kluth 121 S. 8 th Street (1600) Minneapolis, MN 55419 612-373-6900 1 William
More informationIMPACT OF PATENT SETTLEMENTS ON DRUG COSTS: ESTIMATION OF SAVINGS
Providing key policy setters and decision makers in the global health sector with unique and transformational insights into healthcare dynamics derived from granular analysis of information. IMPACT OF
More informationDr. Reddy s Q3 and 9M FY16 Financial Results
Press Release DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS KEDAR UPADHYE kedaru@drreddys.com (Ph: +91-40-66834297) CONTACT
More informationAn integrated global healthcare company
An integrated global healthcare company 1 A Mission to create healthier communities globally Zydus Cadila is dedicated to life In all its dimensions. Our world is shaped by a passion for innovation, commitment
More informationThe Effect of Generic Drug Competition on Generic Drug Prices During the Hatch-Waxman 180-Day Exclusivity Period. Luke M. Olson Brett W.
WORKING PAPERS The Effect of Generic Drug Competition on Generic Drug Prices During the Hatch-Waxman 180-Day Exclusivity Period Luke M. Olson Brett W. Wendling WORKING PAPER NO. 317 April 2013 FTC Bureau
More informationAdopt IP Protections to Ensure Regulatory Exclusivity for Orphan Drugs
30-Second Summary Orphan drugs present unique risks the potential return on investment is inherently constrained by small patient populations and attendant reimbursement challenges. Recognizing these challenges,
More informationPharmaceutical royalties: a new securitisation frontier Malcolm S Dorris Dechert LLP. Dechert LLP 2007
10 Pharmaceutical royalties: a new securitisation frontier Malcolm S Dorris 2007 Securitisation techniques have been increasingly used in less traditional financings involving a wide variety of asset classes.
More informationMarketed Unapproved Drugs: FDA to Take Immediate Enforcement Action at Any Time, Without Prior Notice
Marketed Unapproved Drugs: FDA to Take Immediate Enforcement Action at Any Time, Without Prior Notice Kurt R. Karst Hyman, Phelps & McNamara, P.C. 700 Thirteenth Street, N.W., Suite 1200 Washington, D.C.
More informationFDA s Final Compliance Policy Guide for Marketed Unapproved Drugs Is Agency Enforcement at a Crossroads, or Stuck in a Traffic Circle
FDA s Final Compliance Policy Guide for Marketed Unapproved Drugs Is Agency Enforcement at a Crossroads, or Stuck in a Traffic Circle Kurt R. Karst Associate Hyman, Phelps & McNamara, P.C. 700 Thirteenth
More informationDrug Re-Examination/Data Exclusivity in JAPAN and Neighboring Countries
Japan Pharmaceutical Manufacturers & Association Drug Re-Examination/Data Exclusivity in JAPAN and Neighboring Countries AIPPI Forum & ExCo Workshop Pharma IV September 6, 2013 at Helsinki Yoichi OKUMURA
More informationThe Benefits of Patent Settlements: New Survey Evidence on Factors Affecting Generic Drug Investment
The Benefits of Patent Settlements: New Survey Evidence on Factors Affecting Generic Drug Investment by Bret Dickey 1 Jonathan Orszag 2 July 23, 2013 3 1 Bret Dickey is an Executive Vice President with
More informationAnnual Report on Form 20-F
Annual Report on Form 20-F 2 Teva at a Glance Founded in 1901 by three young pharmacists, today Teva Pharmaceutical Industries Ltd. is a leader in the global pharmaceutical industry, providing medicines
More informationPay-For-Delay Settlements in the Wake of Actavis
Michigan Telecommunications and Technology Law Review Volume 20 Issue 2 2014 Pay-For-Delay Settlements in the Wake of Actavis Michael L. Fialkoff University of Michigan Law School Follow this and additional
More informationEC s Preliminary Pharmaceutical Sector Report: An Aggressive Review of Industry Conduct
FEBRUARY 2009, RELEASE TWO EC s Preliminary Pharmaceutical Sector Report: An Aggressive Review of Industry Conduct Susan A. Creighton & Seth C. Silber Wilson, Sonsini, Goodrich and Rosati EC s Preliminary
More informationANDA CHECKLIST FOR CTD or ectd FORMAT FOR COMPLETENESS and ACCEPTABILITY of an APPLICATION FOR FILING
ANDA CHECKLIST FOR CTD or ectd FORMAT FOR COMPLETENESS and ACCEPTABILITY of an APPLICATION FOR FILING For More Information on Submission of an ANDA in Electronic Common Technical Document (ectd) Format
More informationPetitioner, Respondents.
No. 12-416 IN THE Supreme Court of the United States FEDERAL TRADE COMMISSION, Petitioner, v. WATSON PHARMACEUTICALS, INC., et al., Respondents. ON WRIT OF CERTIORARI TO THE UNITED STATES COURT OF APPEALS
More informationGDUFA Regulatory Science Update
GDUFA Regulatory Science Update Robert Lionberger, Ph.D. Director Office of Research and Standards Office of Generic Drugs Center for Drug Evaluation and Research, FDA GPhA Annual Meeting Feb 9, 2015 Goals
More informationA World Leading Addiction Treatment Company with enormous future potential. JP Morgan Conference, San Francisco January 2016
A World Leading Addiction Treatment Company with enormous future potential JP Morgan Conference, San Francisco January 2016 Forward Looking Statements This presentation contains certain statements that
More informationRachel Kreppel CLINICAL TRIALS: A NEW FORM OF INTELLECTUAL PROPERTY? Introduction
Rachel Kreppel CLINICAL TRIALS: A NEW FORM OF INTELLECTUAL PROPERTY? Introduction Clinical trials are not adequately protected by current forms of intellectual property and should be recognized as a new
More informationGuidance for Industry ANDAs: Stability Testing of Drug Substances and Products
Guidance for Industry ANDAs: Stability Testing of Drug Substances and Products Questions and Answers U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationPATENTS. Pharmaceutical Product Patenting Strategies
PATENTS Pharmaceutical Product Patenting Strategies 1. What is a product patent? A product patent is a patent giving protection to a product as such, e.g. as an apparatus, a device or a chemical compound.
More informationFlamel Technologies Provides Update on Corporate Progress
Flamel Technologies Provides Update on Corporate Progress Clinical Programs Continue to Move Forward Outlines Full Year 2016 Revenue Guidance Lyon, France January 8, 2016 - Flamel Technologies (NASDAQ:
More informationSmall Business Assistance
Small Business Assistance Products Ronald.Wilson@fda.hhs.gov Financial Assistance and Incentives for Research and Development of New Drug/Biologic Ron Wilson, Director of Small Business Assistance Center
More informationHow To Settle A Case With The Ftc
IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA ) FEDERAL TRADE COMMISSION ) 600 Pennsylvania Avenue, N.W. ) Washington, D.C. 20580 ) ) Plaintiff, ) v. ) Civil Action No. 2:08-cv-2141-MSG
More informationGeneric Drug User Fee Act Program Performance Goals and Procedures
Generic Drug User Fee Act Program Performance Goals and Procedures The performance efficiencies, metric goals and procedures to which FDA will agree upon commencement of a generic drug user fee act (GDUFA)
More informationXarelto-API Insights. Brochure More information from http://www.researchandmarkets.com/reports/3043740/
Brochure More information from http://www.researchandmarkets.com/reports/3043740/ Xarelto-API Insights Description: Summary The active pharmaceutical ingredients worldwide market is in continuous development
More informationCanada s Patented Medicines (Notice of Compliance) Regulations: Removing Inefficiencies to Encourage Generic Competition
Canada s Patented Medicines (Notice of Compliance) Regulations: Removing Inefficiencies to Encourage Generic Competition by Suzanne Marie Porter A thesis submitted in conformity with the requirements for
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 20-F
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ANNUAL REPORT PURSUANT TO
More informationThe Hatch-Waxman Framework Before marketing a new drug in the United States, the federal Food, Drug and Cosmetics Act (FDCA) requires a
REPRINTED WITH PERMISSION FROM: IPL NEWSLETTER, A PUBLICATION OF THE ABA SECTION OF INTELLECTUAL PROPERTY LAW VOL. 23, NO. 4 (SUMMER 2005). ALL RIGHTS RESERVED. THIS INFORMATION OR ANY PORTION THEREOF
More informationVolume IX, Issue 1, Fall 2002 CASE ANALYSIS - IN RE BUSPIRONE PATENT AND ANTITRUST LITIGATION
Volume IX, Issue 1, Fall 2002 CASE ANALYSIS - IN RE BUSPIRONE PATENT AND ANTITRUST LITIGATION....Tim Meade..Professor Hildreth..Patent Seminar St. John s University School of Law..4/18/02 Background Section
More informationCLIENT MEMORANDUM. I. The Basics. June 18, 2013
CLIENT MEMORANDUM FTC v. Actavis: Supreme Court Rejects Bright Line Tests for Reverse Payment Settlements; Complex Questions Remain in Structuring Pharmaceutical Patent Infringement Settlements June 18,
More informationGDUFA (Generic Drug User Fee Act): Q&A Session 2 by teleconference
GDUFA (Generic Drug User Fee Act): Q&A Session 2 by teleconference 11 th December at 2pm GMT, 3pm CET and 9am EST (USA) What is new? GDUFA is in force since October 1, 2012 One-time backlog fee required
More informationV enue can have a dramatic impact on Hatch-
Pharmaceutical Law & Industry Report Reproduced with permission from Pharmaceutical Law & Industry Report, 13 PLIR 372, 03/13/2015. Copyright 2015 by The Bureau of National Affairs, Inc. (800-372-1033)
More informationEarning Exclusivity: Generic Drug Incentives and the Hatch- Waxman Act 1. C. Scott Hemphill 2 & Mark A. Lemley 3
Earning Exclusivity: Generic Drug Incentives and the Hatch- Waxman Act 1 C. Scott Hemphill 2 & Mark A. Lemley 3 A quarter- century ago, Congress fundamentally changed the way the FDA approves pharmaceuticals
More informationPharmaceutical royalties: a new securitisation frontier
Pharmaceutical royalties: a new securitisation frontier Dechert LLP This article first appeared in Global Securitisation and Structured Finance 2004, published by Globe White Page Ltd, www.globalsecuritisation.com.
More informationNASDAQ: ATRS. Bank of America Merrill Lynch 2015 Health Care Conference May 13, 2015
NASDAQ: ATRS Bank of America Merrill Lynch 2015 Health Care Conference May 13, 2015 Safe Harbor Statement This presentation may contain forward-looking statements which are made pursuant to the safe harbor
More informationNATCO PHARMA R&D @ core
VISIT NOTE NATCO PHARMA R&D @ core India Equity Research Pharmaceuticals We met Mr. Rajeev Nanapaneni of Natco Pharma. With its superb R&D capabilities, we see Natco way ahead of peers in the midcap space.
More informationAcrux (ASX: ACR) 28 April 2014
Acrux (ASX: ACR) 28 April 2014 FORWARD-LOOKING STATEMENTS 2 This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown
More informationIN RE CARDIZEM & VALLEY DRUG Co.: THE HATCH-WAXMAN ACT, ANTICOMPETITIVE ACTIONS, AND REGULATORY REFORM
ANTITRUST IN RE CARDIZEM & VALLEY DRUG Co.: THE HATCH-WAXMAN ACT, ANTICOMPETITIVE ACTIONS, AND REGULATORY REFORM By Larissa Burford Congress has struggled to establish the proper equilibrium between maintaining
More informationFood and Drug Administration
Center for Drug Evaluation and Research (CDER) Small Business Assistance Program The Information Source for Regulated Domestic and International Small Pharmaceutical Business CAPT Brenda Stodart, USPHS
More informationPharma Lifecycle Management and Brand Defense Strategy. Strategic and Tactical Options for Continuing Your Product Success Story
Pharma Lifecycle Management and Brand Defense Strategy Strategic and Tactical Options for Continuing Your Product Success Story Pharma Lifecycle Management and Brand Defense Strategy 20 July 2014 Terminology
More informationGuidance for Industry
Guidance for Industry Applications Covered by Section 505(b)(2) DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document
More informationXarelto-Drug Insights,2014
Brochure More information from http://www.researchandmarkets.com/reports/2977191/ Xarelto-Drug Insights,2014 Description: Xarelto - Drug Insights, 2014 provides Xarelto marketed details and API Manufacturers
More informationGAO NEW DRUG DEVELOPMENT. Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts
GAO United States Government Accountability Office Report to Congressional Requesters November 2006 NEW DRUG DEVELOPMENT Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering
More informationOveractive Bladder-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
Brochure More information from http://www.researchandmarkets.com/reports/3533933/ Overactive Bladder-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016 Description: SUMMARY The Report,
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F REGISTRATION STATEMENT PURSUANT TO SECTION
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ANNUAL REPORT PURSUANT
More informationIron Deficiency Anemia- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment,
Brochure More information from http://www.researchandmarkets.com/reports/2980507/ Iron Deficiency Anemia- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment Description: Iron Deficiency
More informationTEVA PHARMACEUTICAL INDUSTRIES LIMITED
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Or È ANNUAL REPORT PURSUANT
More informationAntares Pharma, Inc. Princeton South Corporate Center 100 Princeton South, Suite 300 Ewing, NJ 08628 NASDAQ : ATRS. Paul
Antares Pharma, Inc. Princeton South Corporate Center 100 Princeton South, Suite 300 Ewing, NJ 08628 NASDAQ : ATRS Paul Antares Mission: To develop and commercialize self-administered parenteral medicines
More informationTARO PHARMACEUTICAL INDUSTRIES LTD
TARO PHARMACEUTICAL INDUSTRIES LTD FORM 20-F (Annual and Transition Report (foreign private issuer)) Filed 07/02/13 for the Period Ending 03/31/13 Telephone 9143459001 CIK 0000906338 Symbol TARO SIC Code
More informationThe Verizon - Vonage Decision
Implications of the Verizon - Vonage Patent Infringement Judgment Overview The Complaint, Result and Next Steps in the litigation Scope of the Patents Implications of the decision and of various patents
More informationIntegrated Life Cycle Patient Access Solutions that Maximize Brand ROI
Integrated Life Cycle Patient Access Solutions that Maximize Brand ROI August, 2013 Bob Hastings Vice President of Marketing Pharmaceutical brand marketers are facing a paradigm shift in the way they market
More informationIntroduction to Compliance with FDA Labeling and Advertising Requirements
Introduction to Compliance with FDA Labeling and Advertising Requirements Second Annual Pharmaceutical Industry Regulatory and Compliance Summit Dick Kenny FDA History Basic function of government Oldest
More informationMore Uncertainty: What s The Difference Between a Claim and a Theory?
The AIPLA Antitrust News A Publication of the AIPLA Committee on Antitrust Law October 2010 More Uncertainty: What s The Difference By Steven R. Trybus and Sara Tonnies Horton 1 The United States Court
More informationU.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
More informationFebruary 2006 Procedural
Guidance for Industry Reports on the Status of Postmarketing Study Commitments Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997 U.S. Department of Health and
More informationJOHNSON & JOHNSON FORM 10-Q. (Quarterly Report) Filed 05/07/12 for the Period Ending 04/01/12
JOHNSON & JOHNSON FORM 10-Q (Quarterly Report) Filed 05/07/12 for the Period Ending 04/01/12 Address ONE JOHNSON & JOHNSON PLZ NEW BRUNSWICK, NJ 08933 Telephone 732-524-2455 CIK 0000200406 Symbol JNJ SIC
More informationPRESS RELEASE Noida, Tuesday, February 9, 2016 Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida 201301, India Tel.: +91 120 4361000 http://www.jubl.com JUBILANT LIFE SCIENCES Q3 & 9M FY2016 RESULTS JUBILANT
More informationCase 3:15-cv-08128-MLC-LHG Document 1 Filed 11/17/15 Page 1 of 7 PageID: 1
Case 315-cv-08128-MLC-LHG Document 1 Filed 11/17/15 Page 1 of 7 PageID 1 William L. Mentlik Roy H. Wepner Stephen F. Roth Aaron S. Eckenthal LERNER, DAVID, LITTENBERG, KRUMHOLZ & MENTLIK, LLP 600 South
More informationIntroduction to pharmaceutical technology
Introduction to pharmaceutical technology Marie Wahlgren Chapter 1 What is the topics of today Introduction to the course Introduction to the project assignment How to choose a new drug formulation 1 Contacts
More informationMultiple Sclerosis. Current and Future Players. GDHC1009FPR/ Published March 2013
Multiple Sclerosis Current and Future Players GDHC1009FPR/ Published March 2013 Executive Summary Moderate Growth in the Multiple Sclerosis Market is Expected from 2012 2022 GlobalData estimates the 2012
More informationCATEGORY Advertising. CATEGORY Biopharmaceutics. CATEGORY Biosimilarity
CATEGORY Advertising Guidance Agenda: New & Guidances CDER is Planning to Publish During Calendar Year 2016 (See the Good Guidance Practices (GGPs) regulation on this Web page or 21 CFR 10.115 for details
More informationCOMPETITION COMMISSION OF INDIA (Combination Registration No. C-2014/05/170)
COMPETITION COMMISSION OF INDIA Notice under Section 6 (2) of the Competition Act, 2002 given by Sun Pharmaceutical Industries Limited; and Ranbaxy Laboratories Limited Dated: 05.12.2014 Order under Section
More informationSage ERP I White Paper
The Premier Provider of Effective Business Software Solutions National Presence, Local Touch 1.800.4.BLYTHE www.blytheco.com I White Paper Proactive Regulatory Compliance for Biopharmaceutical Global Competitiveness
More informationInformation for Vermont Prescribers of Prescription Drugs (Long Form)
The information on this form is provided pursuant to Vermont law 33 V.S.A. section 2005a which requires this disclosure by pharmaceutical marketers. Information for Vermont Prescribers of Prescription
More informationDOUBLE PATENTING CONSIDERATIONS by Mark Cohen
DOUBLE PATENTING CONSIDERATIONS by Mark Cohen The Federal Circuit recently issued an important decision with respect to restriction practice and obviousness double patenting in Pfizer Inc. v. Teva Pharmaceuticals
More informationNEW CHEMICAL ENTITIES
NEW CHEMICAL ENTITIES PIONEERING PARTNER FOR PEPTIDES With more than 40 years of expertise in peptide synthesis, a track record in process development, large-scale manufacturing and outstanding product
More informationSWOT ANALYSIS OF INDIAN PHARMACEUTICAL INDUSTRY
SWOT ANALYSIS OF INDIAN PHARMACEUTICAL INDUSTRY KAPIL KUMAR*; DR. M. K. KULSHRESHTHA** *RESEARCH SCHOLAR, BHAGWANT UNIVERSITY, AJMER ** DIRECTOR, S. D. COLLEGE OF MANAGEMENT, PANIPAT ABSTRACT The global
More informationDisclosure. This presentation contains forward-looking statements.
Disclosure This presentation contains forward-looking statements. These forward-looking statements are based on management's current expectations and assumptions as of the date of this presentation, and
More informationRichmond Journal of Law & Technology Volume XVIII, Issue 4. By Scott Bergeson*
A VACCINE APPROACH TO THE REVERSE PAYMENT ILLNESS By Scott Bergeson* Cite as: Scott Bergeson, A Vaccine Approach to the Reverse Payment Illness, XVIII RICH. J.L. & TECH. 14, http://jolt.richmond.edu/v18i4/article14.pdf
More informationTHOMSON REUTERS CORTELLIS FOR INFORMATICS. REUTERS/ Aly Song
THOMSON REUTERS CORTELLIS FOR INFORMATICS REUTERS/ Aly Song THOMSON REUTERS CORTELLIS FOR INFORMATICS 1 Table of Contents Table of Contents...1 The challenge... 2 The solution... 2 WHAT CAN YOU DO WITH
More informationRyerson Digital Media Zone Online Resources Patent Essentials
Maya Medeiros Lawyer, Patent Agent, Trademark Agent T: +1 416.216.4823 maya.medeiros@nortonrosefulbright.com http://www.nortonrosefulbright.com/people/99601/maya- medeiros PATENT ESSENTIALS WHAT IS A PATENT?
More informationHybrid or Mixed Marketing Authorization Application in the European Union: Not a Trivial Decision in New Development Programs for Established Drugs
Hybrid or Mixed Marketing Authorization Application in the European Union: Not a Trivial Decision in New Development Programs for Established Drugs Drug Information Journal 00(0) 1-6 ª The Author(s) 2012
More information2015 CMR INTERNATIONAL PHARMACEUTICAL R&D EXECUTIVE SUMMARY
2015 CMR INTERNATIONAL PHARMACEUTICAL R&D EXECUTIVE SUMMARY AUGUST 2015 2 CMR FACTBOOK 2015 EXECUTIVE SUMMARY INTRODUCTION R&D productivity across the global biopharmaceutical industry is a well-documented
More informationHave you experienced severe health issues following the use of Digitek? Have your loved ones suffered adversely or even died - after taking the drug?
*** DIGITEK *** The Fox Law Firm is Reviewing Potential DIGITEK Claims - Death - Psychosis - Nausea - Confusion - Vomiting - Seizure - Hallucinations - Vision problems - Dizziness - Low blood pressure
More informationN a s d a q : I N S Y
N a s d a q : I N S Y Michael L. Babich, President and Chief Executive Officer Darryl S. Baker, Chief Financial Officer Jeffries Healthcare Conference, June 2014 Safe Harbor Statement This presentation
More informationCoventry Health Care of Georgia, Inc. Coventry Health and Life Insurance Company
Coventry Health Care of Georgia, Inc. Coventry Health and Life Insurance Company PRESCRIPTION DRUG RIDER This Prescription Drug Rider is an attachment to the Coventry Health Care of Georgia, Inc. ( Health
More informationAT&T Global Network Client for Windows Product Support Matrix January 29, 2015
AT&T Global Network Client for Windows Product Support Matrix January 29, 2015 Product Support Matrix Following is the Product Support Matrix for the AT&T Global Network Client. See the AT&T Global Network
More informationDrug Pricing System in Japan
Reference Chuikyo - 1 June 6, 2012 Drug Pricing System in Japan April 2012 (Underlined phrases in red in this text: New features and modifications to the current pricing system adopted by the 2012 system
More informationConference Call Transcript
Conference Call Transcript PFE - Pfizer at Morgan Stanley Global Healthcare Conference Event Date/Time: Sep 15, 2009 / 12:35PM GMT 1 THOMSON REUTERS STREETEVENTS www.streetevents.com Contact Us 2009 Thomson
More informationPain Therapeutics, Inc.
Pain Therapeutics, Inc. Pioneers in Preventing Prescription Drug Abuse Remi Barbier President & CEO June 2014 1 Forward-Looking Statements This presentation contains forward-looking statements within the
More informationPaul K. Wotton, Ph.D President and Chief Executive Officer May 2012 AMEX: AIS
Paul K. Wotton, Ph.D President and Chief Executive Officer May 2012 AMEX: AIS Safe Harbor Statement This presentation may contain forward-looking statements which are made pursuant to the safe harbor provisions
More information